| Dr Philip John Baney Iv, MD | |
|
31 Industrial Dr, Hamburg, PA 19526-8778 | |
| (610) 816-2170 | |
| (610) 562-9814 |
| Full Name | Dr Philip John Baney Iv |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 27 Years |
| Location | 31 Industrial Dr, Hamburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245253723 | NPI | - | NPPES |
| 102325198 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD069454L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Southeastern Home Care Services Of Pa, Llc | Elizabethtown, PA | Home health agency |
| Reading Hospital | West reading, PA | Hospital |
| St Joseph Medical Center | Reading, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tower Health Medical Group | 7618889213 | 577 |
News Archive
Anti-microbial antibody formation has been reported in celiac disease. Relatively high positivity rates were observed for the conventional antibodies, for example, ASCA, anti-OmpW, and anti-I2, and they were known to decrease after a successful gluten free-diet. The importance of newly discovered inflammatory bowel disease-associated antibodies (including anti-glycan antibodies and anti-OMP) in celiac disease is not sure.
Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Nearly half of black males and almost 40 percent of white males in the U.S. are arrested by age 23, which can hurt their ability to find work, go to school and participate fully in their communities.
Bacteria-;especially Gram-negative strains-;are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed.
› Verified 1 days ago
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
Anti-microbial antibody formation has been reported in celiac disease. Relatively high positivity rates were observed for the conventional antibodies, for example, ASCA, anti-OmpW, and anti-I2, and they were known to decrease after a successful gluten free-diet. The importance of newly discovered inflammatory bowel disease-associated antibodies (including anti-glycan antibodies and anti-OMP) in celiac disease is not sure.
Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Nearly half of black males and almost 40 percent of white males in the U.S. are arrested by age 23, which can hurt their ability to find work, go to school and participate fully in their communities.
Bacteria-;especially Gram-negative strains-;are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Philip John Baney Iv, MD Po Box 13579, Reading, PA 19612-3579 Ph: (484) 628-0796 | Dr Philip John Baney Iv, MD 31 Industrial Dr, Hamburg, PA 19526-8778 Ph: (610) 816-2170 |
News Archive
Anti-microbial antibody formation has been reported in celiac disease. Relatively high positivity rates were observed for the conventional antibodies, for example, ASCA, anti-OmpW, and anti-I2, and they were known to decrease after a successful gluten free-diet. The importance of newly discovered inflammatory bowel disease-associated antibodies (including anti-glycan antibodies and anti-OMP) in celiac disease is not sure.
Biologics, a limited distribution network partner for IMBRUVICA™ (ibrutinib), is pleased to announce the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules as a single, oral agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.
Nearly half of black males and almost 40 percent of white males in the U.S. are arrested by age 23, which can hurt their ability to find work, go to school and participate fully in their communities.
Bacteria-;especially Gram-negative strains-;are becoming increasingly resistant to current antibiotic drugs, and the development of new classes of antibiotics has slowed.
› Verified 1 days ago
Alejandro Hernandez, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Hawk Ridge Dr, Hamburg, PA 19526 Phone: 610-562-3066 | |
Miguel Chuidian, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 700 Hawk Ridge Dr, Hamburg, PA 19526 Phone: 610-562-3066 Fax: 610-562-3125 | |
Kenneth D Truscott Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Hawk Ridge Dr, Hamburg, PA 19526 Phone: 610-562-3066 Fax: 610-562-3125 | |
Dr. Elisa Giusto, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 700 Hawk Ridge Dr, Hamburg, PA 19526 Phone: 610-562-0977 | |
Adam R. Haydt, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Hawk Ridge Dr, Hamburg, PA 19526 Phone: 610-562-3066 Fax: 610-562-3125 | |
Dr. Andrew Shenoi, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 700 Hawk Ridge Dr, Hamburg, PA 19526 Phone: 610-562-3066 |